급성 신손상(AKI) 치료 시장은 신장 관련 질환의 유병률 증가와 인식 제고로 인해 확대되고 있습니다. 투석, 약물 치료, 지지 요법은 가장 중요한 치료법 중 하나입니다. 기술 개발과 진단 방법의 강화는 모두 시장 개척에 기여하고 있습니다. 이에 따라 시장 규모는 2024년 15억 1,000만 달러를 돌파하고, 2031년에는 25억 6,000만 달러에 달할 것으로 예상됩니다.
당뇨병, 고혈압 등 만성질환의 증가가 AKI 치료제 시장을 주도하고 있습니다. 그러나 개발도상국에서는 치료비 상승과 낮은 인지도가 걸림돌로 작용하고 있습니다. 정부의 노력과 의료 인프라의 개선은 시장 성장에 매우 중요하며, 획기적인 치료제에 대한 지속적인 연구와 함께 시장 성장에 매우 중요한 요소입니다. 급성 신장 질환 치료에 대한 수요 증가로 인해 2024년부터 2031년까지 연평균 6.85%의 시장 성장이 예상됩니다.
급성 신손상 치료 시장 정의/개요
급성 신손상(AKI) 치료는 근본적인 원인 해결, 체액 균형 유지, 신장 기능 지원으로 구성됩니다. 여기에는 약물 치료, 필요한 경우 투석, 전해질 및 노폐물 수준 모니터링, 문제를 피하고 회복을 촉진하기 위한 투석 등이 포함됩니다.
급성 신손상(AKI)의 치료는 근본적인 원인 해결, 신장 기능 회복, 합병증 예방에 중점을 둡니다. 일반적인 치료로는 수분 보충, 전해질 균형, 약물 치료, 투석 등이 있습니다. 조기 진단과 치료는 영구적인 신장 손상을 피하고 환자의 예후를 개선하는 데 매우 중요합니다.
조기 발견, 맞춤형 치료법, 재생의료의 발전이 급성신장병(AKI)의 치료법을 형성합니다. 바이오마커 기반 진단 및 줄기세포 치료와 같은 기술 혁신은 만성 신장병의 진행을 늦추고 신장 기능 전반을 개선하여 환자의 예후를 개선할 것으로 예측됩니다.
만성질환의 증가는 급성 신장 질환 치료 시장의 성장을 촉진할 것인가?
당뇨병과 고혈압을 포함한 만성질환 유병률의 증가는 급성신장병(AKI) 치료제 시장을 이끄는 주요 요인입니다. 미국 질병예방통제센터(CDC)에 따르면, 미국에서는 약 3,700만 명이 만성 신장병(CKD)을 앓고 있지만, 초기에는 발견되지 않는 경우가 많습니다.
NIDDK에 따르면, AKI는 입원 환자의 5-7%에서 발견되며, 중증 환자의 최대 20%가 AKI를 앓고 있다고 합니다. USRDS 2020 Annual Data Report는 메디케어 수혜자의 CKD 유병률 증가를 언급하고 있으며, National Kidney Foundation은 당뇨병과 고혈압이 CKD 환자에게 미치는 영향이 크다는 점을 강조하고 있습니다. 또한, AKI의 유병률이 급격히 증가하여 더 나은 치료가 시급히 필요하다는 것을 강조하고 있습니다.
높은 치료비가 급성 신손상 치료 시장의 걸림돌이 될까?
급성 신손상(AKI)의 치료비용이 높기 때문에 시장 확대가 제한적일 수 있습니다. National Library of Medicine에 게재된 연구에 따르면, AKI 환자의 평균 입원 비용은 2만 4,896달러인 반면, AKI가 아닌 환자의 평균 입원 비용은 1만 3,425달러로 나타났습니다. AKI에 따른 11,471달러의 추가 비용은 국민과 의료 시스템에 상당한 경제적 부담이 될 수 있습니다.
또한, 최신 진단 및 치료 접근법과 관련된 높은 비용은 적시에 효과적인 치료를 받을 수 있는 기회를 방해할 수 있습니다. 이러한 경제적 제약은 특히 의료 자원이 부족하거나 보험 적용이 불충분한 지역에서는 시장 성장을 저해할 수 있습니다.
The Acute Kidney Injury (AKI) therapy market is expanding due to rising prevalence of kidney-related illnesses and increasing awareness. Dialysis, medicine and supportive care are among the most important treatments. Technological developments and enhanced diagnostic methods both contribute to market growth. This is likely to enable the market size surpass USD 1.51 Billion valued in 2024 to reach a valuation of around USD 2.56 Billion by 2031.
Rising chronic disorders such as diabetes and hypertension are propelling the AKI therapy market. However, high treatment costs and low awareness in developing countries provide obstacles. Government initiatives and improvements to healthcare infrastructure are critical for market growth, as is continued research into breakthrough therapeutics. The rising demand for acute kidney injury treatment is enabling the market grow at a CAGR of 6.85% from 2024 to 2031.
Acute Kidney Injury Treatment Market: Definition/ Overview
Acute Kidney Injury (AKI) treatment consists of addressing the underlying cause, maintaining fluid balance and supporting kidney function. This involves drugs, dialysis if necessary and monitoring electrolyte and waste levels to avoid problems and enhance recovery.
Acute kidney injury (AKI) treatment focuses on addressing the underlying cause, restoring kidney function and avoiding complications. Common interventions include hydration control, electrolyte balance, medicine and dialysis. Early diagnosis and treatment are critical for avoiding permanent kidney damage and improving patient outcomes.
Advances in early detection, customized therapeutics and regenerative medicine will shape the treatment of Acute Kidney Injury (AKI). Innovations such as biomarker-based diagnostics and stem cell therapies are projected to enhance patient outcomes by slowing the progression of chronic kidney disease and improving overall kidney function.
Will Rising Prevalence of Chronic Diseases Boost the Growth of Acute Kidney Injury Treatment Market?
The rising incidence of chronic disorders including diabetes and hypertension is a major driver driving the acute kidney injury (AKI) therapy market. According to the Centers for Disease Control and Prevention (CDC), around 37 million US individuals have chronic kidney disease (CKD), which is frequently undetected in the early stages.
According to the NIDDK, AKI affects 5-7% of hospitalized patients and up to 20% of critically ill patients acquire AKI. The USRDS 2020 Annual Data Report cites a rise in CKD prevalence among Medicare beneficiaries, while the National Kidney Foundation emphasizes the significant impact of diabetes and hypertension on CKD patients. Furthermore, the prevalence of AKI has increasing dramatically, highlighting the urgent need for better treatments.
Will High Cost of Treatment Hamper the Acute Kidney Injury Treatment Market?
The high cost of treatment for acute kidney injury (AKI) may limit market expansion. A study published in the National Library of Medicine found that the average hospitalization cost for AKI patients is $24,896, compared to $13,425 for individuals without AKI. This $11,471 additional cost associated with AKI may be a considerable financial burden for people and healthcare systems.
Furthermore, the high costs associated with modern diagnostic and therapeutic approaches may impede access to timely and effective care. This economic constraint may hinder market growth, especially in areas with inadequate healthcare resources or insufficient insurance coverage.
Category-Wise Acumens
Will Decreasing Blood Flow to the Kidneys Drive the Injury Segment?
A decrease in blood supply to the kidneys will cause the acute kidney injury (AKI) phase. Reduced renal perfusion is the major cause of AKI, which is frequently caused by severe dehydration, shock, or heart failure. When blood flow is reduced, the kidneys cannot filter waste adequately, resulting in kidney injury. This pathophysiological mechanism contributes significantly to AKI cases, emphasizing the need of targeting decreased renal perfusion in therapeutic efforts.
The growing awareness and emphasis on controlling and avoiding diseases that cause reduced blood flow to the kidneys is expected to fuel growth in the AKI therapy segment. Early detection and intervention are critical for reducing harm and improving patient outcomes, which encourages the development of focused medicines and diagnostic technologies in this area.
Will Increasing Demand for Managing Kidney Failure by Removing Waste Drive the Dialysis Segment?
The dialysis segment will be driven by an increase in demand for waste removal to manage renal failure. As kidney function deteriorates, dialysis becomes necessary to accomplish the crucial job of removing waste and excess fluid from the blood.
The rise in chronic renal disease, diabetes and hypertension, all of which contribute to kidney failure, emphasizes the importance of effective dialysis solutions. Advances in dialysis technology, as well as increasing awareness of its benefits, help to fuel this trend. With an increasing patient population requiring dialysis, driven by the increasing prevalence of kidney failure, demand for dialysis treatments is likely to rise further, propelling innovation and market expansion in this sector.
Country/Region-wise Acumens
Will High Prevalence of Chronic Diseases Drive the Market in North America?
The rising prevalence of chronic diseases will propel the AKI therapy market in North America. Chronic illnesses common in the region, such as diabetes and hypertension, are important risk factors for acute kidney injury. With millions of people impacted by these disorders, there is an increasing demand for better AKI treatments.
North America's modern healthcare system and high level of care encourage the use of novel medicines and technologies to manage and treat AKI. Furthermore, large investments in R&D, together with increasing awareness of kidney health, contribute to market growth. As chronic disease rates rise, the demand for AKI therapies will stay high, fueling market growth in North America.
Will Increasing Awareness of Kidney Diseases Drive the Market in Asia Pacific Region?
The acute kidney injury (AKI) treatment market in Asia-Pacific will grow due to increasing awareness of kidney illnesses. Growing public and healthcare professional awareness of the prevalence, risk factors and implications of kidney disease is resulting in earlier diagnosis and more proactive treatment. This increasing awareness fuels demand for new diagnostic tools and treatment choices.
Furthermore, educational initiatives and government health programs aiming at improving kidney health help to drive market growth. As the public gets more educated about kidney disease prevention and management, there will be a greater uptake of AKI treatments, driving market growth. Improved awareness contributes to the overall development of healthcare infrastructure and encourages investment in medical technologies, increasing regional market growth.
Competitive Landscape
The acute kidney injury treatment market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions and political support. The organizations are focusing on innovating their product line to serve the vast population in diverse regions.
Some of the prominent players operating in the acute kidney injury treatment market include:
Baxter International, Inc.
Fresenius Medical Care AG & Co KGaA
Braun Melsungen AG
Angion Biomedica Corp
AM-Pharma
Quark Pharmaceuticals, Inc.
Asahi Kasei Medical Co Ltd
LG Chem
Acute Kidney Injury Treatment Market Latest Developments
In March 2021, B. Braun Avitum AG, a major manufacturer of medical equipment and pharmaceutical products and services and CytoSorbents Corporation, a critical care immunotherapy leader commercializing its CytoSorb blood purification technology to treat fatal inflammation, announced the partnership launched a global co-marketing agreement to promote the usage of CytoSorb.
In March 2021, Critical Path Institute (C-Path), a nonprofit organization, announced the commencement of the Acute Kidney Injury (AKI) Project in partnership with the US Food and Drug Administration. The business proposes creating prognostic tools to better anticipate and identify drug-induced kidney damage (DIKI).
In November 2020, Vifor Pharma, a Swiss medicine maker, agreed to pay Angion Biomedica up to USD 80.0 Million for rights to experimental kidney drug ANG-3777